Recent MSK Discoveries & Advances


Memorial Sloan Kettering researchers are relentlessly exploring every aspect of cancer — from basic investigations of cells and molecules to clinical trials of new treatments and population-wide studies of the disease. While our core mission is to translate this knowledge into new strategies to control cancer, many of our investigators are also making scientific progress against other diseases and conditions.

Below are some examples of discoveries and advances that recently were made in our laboratories and clinics, and featured in our news stories.

399 News Items found
SKI immunologist Ming Li
SKI Scientists Identify Potential New ‘Soldier’ for Cancer Immunotherapy
The new cells, which the scientists have dubbed killer innate-like T cells, differ in several notable ways from the conventional target of many immunotherapies.
Charles Sawyers and Elizabeth Wasmuth
With CryoEM, MSK Researchers Obtain Exquisite View of the Androgen Receptor — A Key Protein in Prostate Cancer
The pictures provide new clues about how the androgen receptor interacts with cancer-causing proteins.
An illustration of a fish fin touching a human finger
Hands, Feet, and Fins: The Connection That Explains Acral Melanoma
Sloan Kettering Institute scientists are using zebrafish to understand human skin cancer that attacks the hands and feet.
Dirk Remus and Richard Hite
SKI Scientists Determine Structure of a DNA Damage 'First Responder'
The results of this collaborative project overturn some conventional wisdom about how the DNA repair process works.
A colorful pigeon standing in an urban setting.
SKI Scientists Discover a New Twist on an 80-Year-Old Biochemical Pathway
With the resurgence of interest in cancer metabolism, researchers are coming to realize that there is more to a cell’s biochemistry than once thought.
SKI scientists David Scheinberg and Derek Tan
Sloan Kettering Institute Scientists Retool CAR T Cells to Serve as ‘Micropharmacies’ for Cancer Drugs
These souped-up versions may help overcome some limitations of existing CAR T cells.
Charles Sawyers, a hematologic oncologist at Memorial Sloan Kettering Cancer Center
A Conversation with MSK’s Charles Sawyers: What’s Next for Precision Oncology
Twenty years ago, Charles Sawyers played a pivotal role in the development of Gleevec, a game-changing cancer drug that has gone on to save millions of lives and open doors for research and innovation. In this episode, Dr. Diane Reidy-Lagunes talks with Dr. Sawyers about what’s next in the field of cancer pharmaceuticals. Is another silver bullet on the horizon?
SKI immunologist Andrea Schietinger
Discovery of a Stem-like T Cell in Type 1 Diabetes Holds Potential for Improving Cancer Immunotherapy, Sloan Kettering Institute Scientists Say
As an autoimmune disease, Type 1 diabetes raises important questions about immune cell activity that have broad implications for immunotherapy.
Yonina Murciano-Goroff, Jenny Xue, Bob Li, Piro Lito, and Yulei Zhao.
MSK Researchers Are Learning Why Some Patients Develop Resistance to ‘Landmark’ Lung Cancer Drug
A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.
Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.